Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 1 (January)

1. Androgen dependent regulation of protein kinase A subunits in prostate cancer cells.
   Cell Signal, 19(2): 401-9. [Abstract] [Full-text]
2. The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review.
   Cancer, 109(1): 13-24. [Abstract] [Full-text]
3. Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer.
   Mol Carcinog, 46(1): 24-31. [Abstract] [Full-text]
4. Prostate cancer stem/progenitor cells: identification, characterization, and implications.
   Mol Carcinog, 46(1): 1-14. [Abstract] [Full-text]
5. Nerve growth factor enhances voltage-gated Na+ channel activity and Transwell migration in Mat-LyLu rat prostate cancer cell line.
   J Cell Physiol, 210(3): 602-8. [Abstract] [Full-text]
6. Prostate cancer in fathers with fewer male offspring: the Jerusalem Perinatal Study cohort.
   J Natl Cancer Inst, 99(1): 77-81. [Abstract] [Full-text]
7. Race-specific geography of prostate cancer incidence.
   Int J Health Geogr, 5: 59. [Abstract] [Full-text]
8. Case-control prostate cancer screening studies should not exclude subjects with lower urinary tract symptoms.
   J Clin Epidemiol, 60(2): 176-80. [Abstract] [Full-text]
9. Anti-HER2 cationic immunoemulsion as a potential targeted drug delivery system for the treatment of prostate cancer.
   Cancer Res, 67(1): 269-75. [Abstract] [Full-text]
10. A glycolytic mechanism regulating an angiogenic switch in prostate cancer.
    Cancer Res, 67(1): 149-59. [Abstract] [Full-text]
11. Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells.
    Cancer Res, 67(1): 85-92. [Abstract] [Full-text]
12. Is triple immunostaining with 34betaE12, p63, and racemase in prostate cancer advantageous? A tissue microarray study.
    Am J Clin Pathol, 127(2): 248-53. [Abstract] [Full-text]
13. Cancer progression in the transgenic adenocarcinoma of mouse prostate mouse is related to energy balance, body mass, and body composition, but not food intake.
    Cancer Res, 67(1): 417-24. [Abstract] [Full-text]
14. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells.
    Cancer Res, 67(1): 246-53. [Abstract] [Full-text]
15. p38MAPK activation is involved in androgen-independent proliferation of human prostate cancer cells by regulating IL-6 secretion.
    Biochem Biophys Res Commun, 353(3): 744-9. [Abstract] [Full-text]
16. Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine.
    Biochem Biophys Res Commun, 353(3): 829-34. [Abstract] [Full-text]
17. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    J Urol, 177(2): 757-61. [Abstract] [Full-text]
18. Atrial natriuretic peptide attenuates hypoxia induced chemoresistance in prostate cancer cells.
    J Urol, 177(2): 751-6. [Abstract] [Full-text]
19. Selenomethionine induced transcriptional programs in human prostate cancer cells.
    J Urol, 177(2): 743-50. [Abstract] [Full-text]
20. Open versus laparoscopic radical prostatectomy: a prospective comparison of postoperative urinary incontinence rates.
    J Urol, 177(2): 615-9. [Abstract] [Full-text]
21. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
    J Urol, 177(2): 540-5. [Abstract] [Full-text]
22. Population based study of hormonal therapy and survival in men with metastatic prostate cancer.
    J Urol, 177(2): 535-9. [Abstract] [Full-text]
23. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.
    J Urol, 177(2): 531-4. [Abstract] [Full-text]
24. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE.
    J Urol, 177(2): 526-29; discussion 529-30. [Abstract] [Full-text]
25. The continuing importance of transrectal ultrasound identification of prostatic lesions.
    J Urol, 177(2): 516-20. [Abstract] [Full-text]
26. Development and external validation of an extended repeat biopsy nomogram.
    J Urol, 177(2): 510-5. [Abstract] [Full-text]
27. Prostate specific antigen density correlates with features of prostate cancer aggressiveness.
    J Urol, 177(2): 505-9. [Abstract] [Full-text]
28. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
    J Urol, 177(2): 499-503; discussion 503-4. [Abstract] [Full-text]
29. Relationship between body mass index and prostate cancer screening in the United States.
    J Urol, 177(2): 493-8. [Abstract] [Full-text]
30. Epidemiology and pathophysiology of prostate cancer in African-American men.
    J Urol, 177(2): 444-9. [Abstract] [Full-text]
31. Early detection of cancer: ideas for a debate.
    Crit Rev Oncol Hematol, 61(2): 97-103. [Abstract] [Full-text]
32. Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments.
    Crit Rev Oncol Hematol, 61(2): 176-85. [Abstract] [Full-text]
33. Molecular markers in the diagnosis of prostate cancer.
    Crit Rev Oncol Hematol, 61(2): 104-39. [Abstract] [Full-text]
34. Trends in treatment costs for localized prostate cancer: the healthy screenee effect.
    Med Care, 45(2): 154-9. [Abstract] [Full-text]
35. A prospective evaluation of the short-term impact and recovery of health-related quality of life in men undergoing radical prostatectomy.
    BJU Int, 99(1): 72-6. [Abstract] [Full-text]
36. Early effects of pharmacological androgen deprivation in human prostate cancer.
    BJU Int, 99(1): 60-7. [Abstract] [Full-text]
37. Transdermal oestrogen therapy as a second-line hormonal intervention in prostate cancer: a bad experience.
    BJU Int, 99(1): 53-5. [Abstract] [Full-text]
38. Prostate cancer detection in men with an initial diagnosis of atypical small acinar proliferation.
    BJU Int, 99(1): 49-52. [Abstract] [Full-text]
39. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
    BJU Int, 99(1): 41-5. [Abstract] [Full-text]
40. An immunohistochemical study of chromogranin A and human epidermal growth factor-2 expression using initial prostate biopsy specimens from patients with bone metastatic prostate cancer.
    BJU Int, 99(1): 189-95. [Abstract] [Full-text]
41. Palliative transurethral resection of the prostate: functional outcome and impact on survival.
    BJU Int, 99(1): 56-9. [Abstract] [Full-text]
42. Clinicians' attitudes to prostate cancer peer-support groups.
    BJU Int, 99(1): 68-71. [Abstract] [Full-text]
43. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.
    J Clin Oncol, 25(3): 257-62. [Abstract] [Full-text]
44. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
    Hum Pathol, 38(2): 332-41. [Abstract] [Full-text]
45. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death.
    Cancer, 109(1): 41-7. [Abstract] [Full-text]
46. Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice.
    Cancer Immunol Immunother, 56(2): 217-26. [Abstract] [Full-text]
47. Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment.
    Int J Radiat Oncol Biol Phys, 67(2): 620-9. [Abstract] [Full-text]
48. Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy.
    Int J Radiat Oncol Biol Phys, 67(2): 610-9. [Abstract] [Full-text]
49. How does performance of ultrasound tissue typing affect design of prostate IMRT dose-painting protocols?
    Int J Radiat Oncol Biol Phys, 67(2): 362-8. [Abstract] [Full-text]
50. Endorectal MRI assessment of local relapse after surgery for prostate cancer: A model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure.
    Int J Radiat Oncol Biol Phys, 67(2): 356-61. [Abstract] [Full-text]
51. Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique.
    Int J Radiat Oncol Biol Phys, 67(2): 347-55. [Abstract] [Full-text]
52. Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation.
    Int J Radiat Oncol Biol Phys, 67(2): 342-6. [Abstract] [Full-text]
53. Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspase-dependent and caspase-independent cell death pathways.
    Life Sci, 80(8): 767-74. [Abstract] [Full-text]
54. 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes inhibit growth, induce apoptosis, and decrease the androgen receptor in LNCaP prostate cancer cells through peroxisome proliferator-activated receptor gamma-independent pathways.
    Mol Pharmacol, 71(2): 558-69. [Abstract] [Full-text]
55. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
    Int J Radiat Oncol Biol Phys, 67(2): 327-33. [Abstract] [Full-text]
56. Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: A 12-year Canadian experience.
    Int J Radiat Oncol Biol Phys, 67(2): 334-41. [Abstract] [Full-text]
57. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer.
    Eur Urol, 51(3): 605-13; discussion 613. [Abstract] [Full-text]
58. Preoperative and intraoperative risk factors for side-specific positive surgical margins in laparoscopic radical prostatectomy for prostate cancer.
    Eur Urol, 51(3): 764-71. [Abstract] [Full-text]
59. Vattikuti Institute prostatectomy: contemporary technique and analysis of results.
    Eur Urol, 51(3): 648-57; discussion 657-8. [Abstract] [Full-text]
60. Robotic-assisted laparoscopic prostatectomy: functional and pathologic outcomes with interfascial nerve preservation.
    Eur Urol, 51(3): 755-62; discussion 763. [Abstract] [Full-text]
61. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy.
    Eur Urol, 51(3): 665-74; discussion 674. [Abstract] [Full-text]
62. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial.
    Eur Urol, 51(3): 659-64. [Abstract] [Full-text]
63. Optimal sampling sites for repeat prostate biopsy: a recursive partitioning analysis of three-dimensional 26-core systematic biopsy.
    Eur Urol, 51(3): 675-82; discussion 682-3. [Abstract] [Full-text]
64. Radical prostatectomy in Austria: a nationwide analysis of 16,524 cases.
    Eur Urol, 51(3): 684-8; discussion 689. [Abstract] [Full-text]
65. Local injection of a sustained-release antiandrogen formulation into a target prostatic site: an experimental study.
    BJU Int, 99(1): 202-6. [Abstract] [Full-text]
66. The association between local atherosclerosis and prostate cancer.
    BJU Int, 99(1): 46-8. [Abstract] [Full-text]
67. Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers.
    Br J Cancer, 96(2): 352-6. [Abstract] [Full-text]
68. Evaluation of the cancer chemopreventive efficacy of rice bran in genetic mouse models of breast, prostate and intestinal carcinogenesis.
    Br J Cancer, 96(2): 248-54. [Abstract] [Full-text]
69. Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms.
    Br J Cancer, 96(2): 269-76. [Abstract] [Full-text]
70. Secondary prostatic adenocarcinoma: a cytopathological study of 50 cases.
    Diagn Cytopathol, 35(2): 91-5. [Abstract] [Full-text]
71. Androgen receptor decoy molecules block the growth of prostate cancer.
    Proc Natl Acad Sci U S A, 104(4): 1331-6. [Abstract] [Full-text]
72. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
    Cancer, 109(3): 477-86. [Abstract] [Full-text]
73. Cumulative cost pattern comparison of prostate cancer treatments.
    Cancer, 109(3): 518-27. [Abstract] [Full-text]
74. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Cancer, 109(3): 536-41. [Abstract] [Full-text]
75. Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer.
    Am J Surg Pathol, 31(2): 311-8. [Abstract] [Full-text]
76. High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features--initial experience.
    Radiology, 242(2): 483-9. [Abstract] [Full-text]
77. Reducible poly(amido ethylenimine) directed to enhance RNA interference.
    Biomaterials, 28(10): 1912-7. [Abstract] [Full-text]
78. Prostate cancer metastasis to clivus causing cranial nerve VI palsy.
    Optometry, 78(2): 55-62. [Abstract] [Full-text]
79. Goserelin acetate in combination with radiotherapy for prostate cancer.
    Expert Opin Pharmacother, 8(2): 257-64. [Abstract] [Full-text]
80. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
    Clin Chem, 53(2): 233-40. [Abstract] [Full-text]
81. Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth.
    Mol Endocrinol, 21(2): 343-58. [Abstract] [Full-text]
82. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
    J Clin Oncol, 25(4): 431-6. [Abstract] [Full-text]
83. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
    J Clin Oncol, 25(4): 349-55. [Abstract] [Full-text]
84. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors.
    Proc Natl Acad Sci U S A, 104(5): 1655-60. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.